Opportunities

Director Medical Affairs, Dermatology (Remote)

Who We Are:

AVITA Medical is a Class III medical device company looking for a full-time Director Medical Affairs, Dermatology to help sustain our expanding line of indications. AVITA is headquartered in Valencia, CA, and manufactures in Ventura, CA. Come join our team and be part of our growth!

What We Are Looking For:

The Director Medical Affairs, Dermatology is a key contributor to the company’s clinical and commercial development with responsibility for establishing, developing, and maintaining relationships with prominent experts in the therapeutic areas where AVITA Medical skin regeneration products are sold.

The Director Medical Affairs, Dermatology will work with AVITA’s customers, internal stakeholders, outside vendors, and clinical staff on clinical research programs in support of pre-market and post-market initiatives.  The Director Medical Affairs, Dermatology will be responsible for collaborating with KOLs on research and education initiatives as well as overseeing the MSL team in the dermatology space.

Additionally, the Director Medical Affairs, Dermatology will be responsible for building awareness of AVITA products and clinical outcomes, preparing educational materials, and delivering educational programs within the dermatological space.  The Director will work cross-functionally to ensure compliant delivery of materials.  The Director Medical Affairs, Dermatology will also be integral in mitigating errors and improving safety of AVITA’s products in the dermatology space.

Duties/Responsibilities

  • Oversee MSL – Derm Team
  • Serve as subject matter expert for repigmentation diseases and other dermatological conditions
  • Develop education tools for internal and external training programs
  • Build strategy for medical communications including conference abstract submissions and presentations
  • Lead publication planning and journal manuscript submissions
  • Prepare data presentations based on scientific and clinical data and present information to both internal and external stakeholders
  • Support preparation of abstracts and manuscripts for both company sponsored and IIS programs
  • Build awareness of RECELL technology by interfacing and soliciting advisory input from external experts and health care professionals at major dermatology conferences, advisory boards, and other external meetings
  • Contribute to payer access strategy and oversee medical affairs involvement in post-market study activities
  • Work collaboratively with cross functional team in lifecycle management, competitive intel, risk assessment, payer access, & business development opportunities

Special Knowledge/Skills

  • Understanding of current clinical and scientific trends in dermatological space, pigmentation disorders, and dermatological surgical procedures and techniques
  • KOL development and engagement in dermatology
  • Understanding of clinical trial design, protocol development, regulatory pathways, and medical communication strategy
  • Excellent written and oral communication skills with proficiency in Microsoft word and PowerPoint
  • Ability to work independently and as a member of a team
  • Capable of managing multiple projects simultaneously
  • MSL strategy and oversight

Experience

  • 5+ years in medical affairs role
  • 3+ years as a MSL
  • Medical writing
  • Publication planning, conference strategy
  • Interpretation and dissemination of pre-clinical and clinical data
  • Project leadership
  • Experience with new product launch
  • KOL development

Education/Training

  • Advanced degree in medical field, life sciences, or public health
  • Experience in dermatological diseases preferred

Travel Expectations

  • Up to 75% travel may be required for KOL development, conference attendance, and in-person corporate meetings

Position Location

  • US

Information Security Compliance

AVITA Medical recognizes the role of information security in ensuring that users have access to the information they require to carry out their work in a secure manner.  AVITA Medical is committed to protecting the security of its information and information systems.  As such, each role within AVITA Medical must demonstrate the same commitment to information security.

IMPORTANT SAFETY INFORMATION (United States)

INDICATIONS FOR USE: The RECELL® Autologous Cell Harvesting Device is indicated for the treatment of acute thermal burn wounds. The RECELL® device is used by an appropriately-licensed healthcare professional at the patient’s point of care to prepare autologous RES® Regenerative Epidermal Suspension for direct application to acute partial-thickness thermal burn wounds in patients 18 years of age and older or application in combination with meshed autografting for acute full-thickness thermal burn wounds in pediatric and adult patients.

CONTRAINDICATIONS: RECELL® is contraindicated for: the treatment of wounds clinically diagnosed as infected or with necrotic tissue, the treatment of patients with a known hypersensitivity to trypsin or compound sodium lactate (Hartmann’s) solution, patients having a known hypersensitivity to anesthetics, adrenaline/epinephrine, povidone-iodine, or chlorhexidine solutions.

WARNINGS AND PRECAUTIONS: Autologous use only. Wound beds treated with a cytotoxic agent (e.g., silver sulfadiazine) should be rinsed prior to application of the cell suspension. RECELL® is provided sterile and is intended for single-use. Do not use if packaging is damaged or expired. Choose a donor site with no evidence of cellulitis or infection and process skin immediately. A skin sample should require between 15 and 30 minutes contact with Enzyme. Contact in excess of 60 minutes is not recommended. RECELL® Enzyme is animal derived and freedom from infectious agents cannot be guaranteed.

PRECAUTIONS: RECELL® is not intended for use without meshed autograft for treatment of full-thickness burn wounds. The safety and effectiveness of RECELL® without meshed autograft have not been established for treatment of partial-thickness burn wounds: on the hands and articulating joints, >320 cm2, in patients with wounds totaling >20% total body surface area (TBSA). The safety and effectiveness of RECELL with autografting have not been established for treatment of full-thickness burn wounds: on the hands and articulated joints, and in patients younger than 28 days of age (neonates).

SPECIAL PATIENT POPULATIONS: The safety and effectiveness of RECELL® have not been established for treatment of acute thermal partial-thickness burn wounds in pediatric patients younger than 18 years of age.

For complete Important Safety Information, refer to Instructions For Use. Please be aware that any indication for RECELL® outside of the United States may differ from the US indication. Please see the Instructions for Use for each country for the specific indication of RECELL®.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to AVITA, its subsidiaries or affiliates. No use of any AVITA trademark, trade name, or trade dress in this site may be made without the prior written authorization of AVITA, except to identify the product or services of the company.
©Copyright 2022 AVITA Medical. All Rights Reserved.
Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to AVITA, its subsidiaries or affiliates. No use of any AVITA trademark, trade name, or trade dress in this site may be made without the prior written authorization of AVITA, except to identify the product or services of the company.
©Copyright 2022 AVITA Medical. All Rights Reserved.